Evofem Announces Issuance of New U.S. Patent Covering Phexxi Composition of Matter
— Issuance of U.S. Patent No. 11,992,472 Further Strengthens Evofem’s Intellectual Patent Portfolio —
— Newly issued patent is Evofem’s fifth covering Hormone-Free “In the Moment” Contraceptive Phexxi in the United States —
Related news for (EVFM)
- FDA Orange Book Lists New U.S. Patent for SOLOSEC, Evofem Biosciences’ “One and Done” Oral Treatment for Bacterial Vaginosis and Trichomoniasis
- Evofem Biosciences to Present at Emerging Growth Conference
- Windtree Therapeutics Strikes Deal to Source PHEXXI, Signaling Revenue-Driven Pivot
- Evofem Biosciences Announces Financial Results for the Third Quarter of 2024
- Evofem Biosciences Announces Financial Results for the Second Quarter of 2024